Grifols, an EU-headquartered leader in plasma collection and fractionation of plasma derived medicinal products (PDMPs), welcomes the opportunity to provide input on the pharmaceutical strategy. As the roadmap noted, the EU is not as competitive as it could be: the current framework lacks dynamism and is not well suited to promote innovation.
GS
Grifols, S.A.
Company · Spain · EU Transparency Register 400747536239-04
4
positions filed
in the 583 files tracked
3
legislative files
of 583 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1048 companies & groups on this site, they rank #343 by legislative files engaged — a count of participation, not a measure of influence.
1.2
declared lobbying FTE
self-declared
€25K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2019
in the register since
Declares membership of
- Plasma Protein Therapeutics Association (PPTA)
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) →
- MedTech Europe →
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Companies & groups
- Head office
- San Cugat del Valles, Spain
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Grifols, in PolicySpeak: request access →
Work at Grifols, S.A.? so we know who speaks for it.
Their record over time
Grifols, S.A. filed 4 positions between 13 Dec 2020 and 8 Sept 2022, across 3 of the 583 legislative files tracked here, attaching a full position paper 1 time.
2020 · 1 filed2021 · 2 filed2022 · 1 filed
What they argued
Grifols welcomes the adoption of the proposal for a Regulation on standards of quality and safety for substances of human origin (SoHO). The proposal is an important step to modernise the SoHO regulatory framework and has the potential to increase the supply of essential medicines for patients reliant on plasma therapies for rare, chronic and life-threatening conditions.
Grifols welcomes the opportunity to provide input to the Inception Impact Assessment for the revision of the BTC legislation. This legislation has helped standardize quality and safety requirements for blood, tissues and cells but it has not adapted to an evolving reality for blood establishments and patients who rely on blood products.
Grifols welcomes the opportunity to provide input on the Regulation on serious cross-border health threats. During recent public health crises, including COVID-19 and Ebola, Grifols has contributed our expertise in the development of plasma-derived therapeutics and diagnostics to aid in the response to these health emergencies. We look forward to working with the Commission to improve resilience.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Grifols, S.A. next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 39.
Is this your organization?
Everything on this page comes from Grifols, S.A.’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.